This article has been updated from a previous version to include comments from Qiagen and Abbott spokespersons.

By Ben Butkus

Qiagen and Abbott said yesterday that they have inked a broad licensing and commercialization deal intended to significantly strengthen the in vitro diagnostic test menus available in North America on each company's automated, real-time PCR-based instrument platform.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.